EUnetHTA Joint Action 3 (2016-20) JA3-WP4
2017 - PDF

This is the assessment of the relative effectiveness of “Alectinib (Alecensa©) as monotherapy for the first line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC)".

This is a revised version of the report originally posted on January 23, 2018. An error was identified in table 0.1 and table A21, in which the results of the ORR were inputted in reverse for alectinib and crizotinib. This is now corrected in the revised version. The final version of the assessment was published in January 2018.

Below is the documentation provided by the Joint Assessment authoring team: